Deepinder Goyal’s new venture, Temple, has opened a waitlist for its premium brain-monitoring wearable priced at ₹85,000. With pre-orders starting November 1 and a boutique manufacturing strategy, the venture targets a niche health-conscious audience. Investors may note the high entry price and the regulatory complexities involved in marketing medical-grade hardware.
Deepinder Goyal, co-founder of Zomato, has opened the waitlist for his latest venture, Temple, which aims to enter the niche market of brain-monitoring wearables. The device is priced at ₹85,000, placing it well above typical mass-market consumer fitness trackers. Interested users can now register on the portal, with official pre-orders scheduled to begin on November 1. This launch marks a distinct pivot into the premium wellness hardware space, focusing on capturing granular insights into cerebral blood flow and oxygenation levels.
The business model for Temple appears to rely on a highly curated approach rather than a mass-market rollout. The company requires applicants to provide detailed professional and personal information, which will be used to select users who can offer substantive feedback. This suggests that the firm is prioritizing product development through a small group of early adopters rather than seeking immediate scale. Each unit is described as hand-assembled, with a delivery timeline currently estimated at three months from the purchase date.
For observers, the product’s premium pricing and its position as a device offering health insights raise specific questions regarding regulatory compliance. In India, hardware claiming to monitor specific health metrics—especially neurological data—is subject to strict standards. Market participants tracking the health-tech sector may watch for how the company handles certifications, user data privacy, and the long-term demand for such high-cost wearables. Ensuring that the device meets safety and medical-grade standards is a significant hurdle for any new entrant in the health hardware space.
The venture also presents a clear distinction from the consumer services typically associated with Goyal’s roles in listed companies. The decision to offer a limited launch edition that includes lifetime software access and specialized medical-grade supplies indicates a focus on building a loyal, high-paying user base. The success of this initiative will likely depend on whether the health insights provided by the device justify the high price point for a small segment of the market, as well as the company’s ability to execute its assembly and delivery timelines without the cost advantages of large-scale manufacturing.